Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of ...

Happily for investors, Pfizer is generating enough cash flow to cover its dividend. In 2024, it paid $9.5 billion in ...

The old idiom "blink, and you'll miss it" might be the best descriptor of the historic volatility we've witnessed on Wall ...

Denise Bronner, Ph.D., makes the case for and against acquisitions for rejuvenating Big Pharma pipelines. She explains why outsourcing innovation can be as risky, and costly, as internal discovery.

Dividend-paying stocks have consistently attracted investor interest due to their long-term value. CNBC highlights this by ...

You may know 175-year-old pharmaceutical company Pfizer (NYSE: PFE) best for its COVID-19 vaccine, but investors have long ...

Pfizer shows promise. The company has positioned itself for growth in oncology, including a $43 billion acquisition of Seagen to boost its pipeline. Plus, Pfizer could enter the hot GLP-1 agonist ...

Pfizer’s multi-year lows reflect headwinds, lack of catalysts, and fading appeal to both growth and defensive investors. Read why PFE stock is a hold.

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Bank of America Corporation (BAC), ...

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued stocks in the Pharmaceuticals industry for Tuesday, April 15, 2025. Let’s ...

ECHELON-3 (NCT04404283) principal investigator Craig A. Portell, MD, speaks to the significance of this triplet approval from ...

Seagen's deal – covering a drug candidate called LAVA-1223 – is in preclinical development and is designed to target and activate gamma delta T-cells in the presence of EGFR-expressing tumour ...